Michael Deppe - Quest Diagnostics President
| DGX Stock | USD 151.92 0.96 0.64% |
President
Mr. Michael J. Deppe is Vice President, Corporationrationrate Controller and Chief Accounting Officer and Principal Accounting Officer of the Company. He has served in various account and finance leadership roles since joining the Company in 1998. He served as Vice President, Finance Enterprise Operations and IT from August 2015 to March 2019, Executive Director, Finance Financial Planning and Analysis Management Reporting from January 2013 to August 2015, and as Assistant Corporationrationrate Controller from February 2006 to December 2012. Mr. Deppe joined the Company after starting his career at Pricewater house Coopers. since 2019.
| Age | 58 |
| Tenure | 6 years |
| Address | 500 Plaza Drive, Secaucus, NJ, United States, 07094 |
| Phone | 973 520 2700 |
| Web | https://www.questdiagnostics.com |
Michael Deppe Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Deppe against Quest Diagnostics stock is an integral part of due diligence when investing in Quest Diagnostics. Michael Deppe insider activity provides valuable insight into whether Quest Diagnostics is net buyers or sellers over its current business cycle. Note, Quest Diagnostics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Quest Diagnostics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Deppe over three months ago Disposition of tradable shares by Michael Deppe of Quest Diagnostics at 125.02 subject to Rule 16b-3 |
Quest Diagnostics Management Efficiency
The company has Return on Asset of 0.0566 % which means that on every $100 spent on assets, it made $0.0566 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1322 %, implying that it generated $0.1322 on every 100 dollars invested. Quest Diagnostics' management efficiency ratios could be used to measure how well Quest Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.10 in 2025, whereas Return On Tangible Assets are likely to drop 0.14 in 2025. At this time, Quest Diagnostics' Other Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 7.66 in 2025, whereas Total Assets are likely to drop slightly above 8.5 B in 2025.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Diarmaid Cunningham | ICON PLC | 50 | |
| Michael Tang | Agilent Technologies | 50 | |
| Eric Sherbet | IQVIA Holdings | 60 | |
| Birgit Girshick | Charles River Laboratories | 55 | |
| Sherry Buck | Waters | 55 | |
| Robert Carson | Waters | 46 | |
| Richard III | IQVIA Holdings | 62 | |
| Elizabeth Rae | Waters | 60 | |
| Samraat Raha | Agilent Technologies | 51 | |
| Robert McMahon | Agilent Technologies | 55 | |
| Rose Kidd | ICON PLC | N/A | |
| Kevin Knightly | IQVIA Holdings | 63 | |
| Jon Resnick | IQVIA Holdings | N/A | |
| Riaz MBA | Sotera Health Co | 54 | |
| William Barbo | Charles River Laboratories | 64 | |
| Paula Green | Twist Bioscience Corp | 57 | |
| John Lynch | Waters | N/A | |
| Ian King | Waters | 63 | |
| Dominique Grau | Agilent Technologies | 66 | |
| Rob Kotchie | IQVIA Holdings | N/A | |
| Simon Holmes | ICON PLC | 57 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0566 |
Quest Diagnostics Leadership Team
Elected by the shareholders, the Quest Diagnostics' board of directors comprises two types of representatives: Quest Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quest. The board's role is to monitor Quest Diagnostics' management team and ensure that shareholders' interests are well served. Quest Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quest Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Plewman, Senior Services | ||
| Garry Clark, Senior Officer | ||
| Gail Wilensky, Independent Director | ||
| Kristin Esq, Senior Officer | ||
| Stephen Rusckowski, CEO and President Director and Member of Executive Committee | ||
| Murali Balakumar, Chief VP | ||
| Wright Lassiter, Independent Director | ||
| Gary Pfeiffer, Independent Director | ||
| Vicky Gregg, Independent Director | ||
| Cecilia McKenney, Senior Officer | ||
| Helen Torley, Independent Director | ||
| Michael Prevoznik, Senior Vice President General Counsel | ||
| Tracey Doi, Independent Director | ||
| Karthik Kuppusamy, Senior Solutions | ||
| Catherine Doherty, Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing | ||
| Manuel Mendez, Senior Vice President Chief Commercial Officer | ||
| Gabrielle Wolfson, Senior Vice President and Chief Information and Digital Officer | ||
| Carrie Manner, Senior Vice President - Advanced Diagnostics | ||
| Sam Samad, Executive CFO | ||
| Dermot Shorten, MA Strategy | ||
| Shawn Bevec, Executive Director Investor Relations | ||
| Timothy Main, Independent Director | ||
| Michael Deppe, Vice President Corporate Controller and Chief Accounting Officer and Principal Accounting Officer | ||
| Mark Guinan, Chief Financial Officer, Executive Vice President | ||
| Daniel Stanzione, Non-Executive Chairman of the Board | ||
| Gary Samuels, Senior Officer | ||
| Michael JD, Senior Counsel | ||
| Denise Morrison, Independent Director | ||
| James Davis, Executive Vice President, General Diagnostics | ||
| Timothy Ring, Lead Independent Director |
Quest Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quest Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0566 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 23.16 B | ||||
| Shares Outstanding | 111.61 M | ||||
| Shares Owned By Insiders | 0.40 % | ||||
| Shares Owned By Institutions | 91.55 % | ||||
| Number Of Shares Shorted | 1.91 M | ||||
| Price To Earning | 14.57 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for Quest Stock Analysis
When running Quest Diagnostics' price analysis, check to measure Quest Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest Diagnostics is operating at the current time. Most of Quest Diagnostics' value examination focuses on studying past and present price action to predict the probability of Quest Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest Diagnostics' price. Additionally, you may evaluate how the addition of Quest Diagnostics to your portfolios can decrease your overall portfolio volatility.